← Back to Clinical Trials
Recruiting NCT03966872

NCT03966872 Comparative Effectiveness of IIMR Versus CDSMP

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03966872
Status Recruiting
Phase
Sponsor Dartmouth-Hitchcock Medical Center
Condition Mental Illness
Study Type INTERVENTIONAL
Enrollment 600 participants
Start Date 2019-09-02
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Integrated Illness Management and RecoveryChronic Disease Self-Management Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 600 participants in total. It began in 2019-09-02 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study will enroll 600 people with serious mental illness who receive services at Centerstone in KY or TN and will compare two different evidence-based self-management interventions: Integrated Illness Management and Recovery (I-IMR), a program developed by the study team at Dartmouth that trains people with serious mental illness on physical and mental health self-management, and the Stanford Chronic Disease Self-Management Program (CDSMP), a program largely focused on physical health self-management that has been used widely in the general population.

Eligibility Criteria

Inclusion Criteria: * Serious Mental Illness (diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or chronic depression with moderate impairment in functioning) receiving services at Centerstone(KY and TN) * Diagnosis of a chronic medical condition increasing risk of early mortality from cardiovascular or respiratory disease (e.g., diabetes, hyperlipidemia, hypertension, COPD, heart failure, tobacco dependence, obesity), and at least 1 ER visit or hospitalization within the past year or judgment by the treatment team of substantial need for illness self-management training. Exclusion Criteria: * Consumers who do not speak English * Consumers with either no, or a well-controlled medical condition will not be included * Individuals residing in a nursing home or other institution * Evidence of significant cognitive impairment as indicated by a Mini Mental Status Examination score \<24, will be excluded Eligibility for the COVID -related substudy is dependent on enrollment and participation in the parent project.

Contact & Investigator

Central Contact

Meghan Santos, MSW

✉ Meghan.M.Santos@Dartmouth.edu

📞 603-226-6804

Principal Investigator

Sarah Pratt

PRINCIPAL INVESTIGATOR

Dartmouth-Hitchcock Medical Center

Frequently Asked Questions

Who can join the NCT03966872 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mental Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03966872 currently recruiting?

Yes, NCT03966872 is actively recruiting participants. Contact the research team at Meghan.M.Santos@Dartmouth.edu for enrollment information.

Where is the NCT03966872 trial being conducted?

This trial is being conducted at Louisville, United States, Nashville, United States.

Who is sponsoring the NCT03966872 clinical trial?

NCT03966872 is sponsored by Dartmouth-Hitchcock Medical Center. The principal investigator is Sarah Pratt at Dartmouth-Hitchcock Medical Center. The trial plans to enroll 600 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology